<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-QILBFZTL/b5a00638-aae6-4859-8941-736fddb06cc4/PDF"><dcterms:extent>288 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-QILBFZTL/ac14742e-7d9f-43d0-bdb2-49af91791a98/TEXT"><dcterms:extent>65 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="1997-2025"><edm:begin xml:lang="en">1997</edm:begin><edm:end xml:lang="en">2025</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:doc-QILBFZTL"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/URN:NBN:SI:spr-S2P9OQWZ" /><dcterms:issued>2024</dcterms:issued><dc:creator>Ivkovič, Jakob</dc:creator><dc:contributor>Ivkovič, Jakob</dc:contributor><dc:creator>Unk, Mojca</dc:creator><dc:format xml:lang="sl">številka:2, ahead of print</dc:format><dc:format xml:lang="sl">letnik:28</dc:format><dc:format xml:lang="sl">str. 1-21</dc:format><dc:identifier>DOI:10.25670/oi2024-009on</dc:identifier><dc:identifier>ISSN:1408-1741</dc:identifier><dc:identifier>COBISSID_HOST:208991747</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-QILBFZTL</dc:identifier><dc:language>sl</dc:language><dc:publisher xml:lang="sl">Onkološki inštitut Ljubljana</dc:publisher><dcterms:isPartOf xml:lang="sl">Onkologija (Ljubljana)</dcterms:isPartOf><dc:subject xml:lang="en">cancerogenesis</dc:subject><dc:subject xml:lang="sl">črevesni mikrobiom</dc:subject><dc:subject xml:lang="en">gut microbiome</dc:subject><dc:subject xml:lang="en">immune checkpoint inhibitors</dc:subject><dc:subject xml:lang="en">immunotherapy</dc:subject><dc:subject xml:lang="sl">imunoterapija</dc:subject><dc:subject xml:lang="sl">kancerogeneza</dc:subject><dc:subject xml:lang="sl">zaviralci imunskih nadzornih točk</dc:subject><dcterms:temporal rdf:resource="1997-2025" /><dc:title xml:lang="sl">Črevesni mikrobiom pri bolnikih z rakom| Gut microbiome in cancer patients|</dc:title><dc:description xml:lang="sl">The gut microbiome represents the genetic makeup of all the microbes in the human digestive tract. It contains about 38 trillion microorganisms with more than three million genes. With the development of new sequencing techniques, in-depth research of the human microbiome, which is involved in the metabolism of nutrients, and drugs, maintains a barrier of the intestinal mucosa, protects against pathogenic microorganisms, and can alter the host's immune response. There is compounding evidence, that the microbiome is involved in the development of certain malignant diseases and affects the effectiveness of oncological treatment, specifically on immunotherapy. Currently, the understanding of the numerous complex interactions between the gut microbiome, the host immune system, diet, drugs, and malignant cells is based on smaller retrospective and observational studies. This paper aims to review the available data on the microbiome and our current understanding of the human microbiome's role in cancer patients</dc:description><dc:description xml:lang="sl">Črevesni mikrobiom predstavlja genetsko zasnovo vseh mikrobov, ki obstajajo v človeškem prebavnem traktu in vsebuje okoli 38 bilijonov mikroorganizmov, ki kodira več kot tri milijone genov. Razvoj novih tehnik molekularnega sekvenciranja je omogočil poglobljeno raziskovanje človeškega mikrobioma, ki je vpleten v presnovo hranil, zdravil, vzdržuje celovito bariero črevesne sluznice, varuje pred patogenimi mikroorganizmi in lahko spreminja imunski odziv gostitelja. Vedno več je dokazov, da je črevesni mikrobiom vpleten v razvoj nekaterih malignih bolezni in vpliva na učinkovitost onkološkega zdravljenja, predvsem na imunoterapijo. Sedanje razumevanje številnih zapletenih interakcij med črevesnim mikrobiomom, gostiteljevim imunskim sistemom, prehrano, zdravili in malignimi celicami temelji na manjših retrospektivnih in opazovalnih raziskavah. Namen tega prispevka je pregled razpoložljivih podatkov o mikrobiomu in naše dosedanje razumevanje vloge črevesnega mikrobioma pri bolnikih z rakom</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:doc-QILBFZTL"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:doc-QILBFZTL" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:doc-QILBFZTL/b5a00638-aae6-4859-8941-736fddb06cc4/PDF" /><edm:rights rdf:resource="http://creativecommons.org/licenses/by/4.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Onkološki inštitut Ljubljana</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:doc-QILBFZTL/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:doc-QILBFZTL" /></ore:Aggregation></rdf:RDF>